KW-2449
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myelogenous Leukemia (AML)
Conditions
Acute Myelogenous Leukemia (AML)
Trial Timeline
Jan 1, 2009 → Dec 1, 2010
NCT ID
NCT00779480About KW-2449
KW-2449 is a phase 1 stage product being developed by Kyowa Kirin for Acute Myelogenous Leukemia (AML). The current trial status is terminated. This product is registered under clinical trial identifier NCT00779480. Target conditions include Acute Myelogenous Leukemia (AML).
What happened to similar drugs?
20 of 20 similar drugs in Acute Myelogenous Leukemia (AML) were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00779480 | Phase 1 | Terminated |
| NCT00346632 | Phase 1 | Terminated |
Competing Products
20 competing products in Acute Myelogenous Leukemia (AML)